273 related articles for article (PubMed ID: 27983753)
21. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
[TBL] [Abstract][Full Text] [Related]
22. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
23. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
[TBL] [Abstract][Full Text] [Related]
25. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
26. Tigecycline: a new glycylcycline antimicrobial agent.
Kasbekar N
Am J Health Syst Pharm; 2006 Jul; 63(13):1235-43. PubMed ID: 16790575
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
Gardiner D; Dukart G; Cooper A; Babinchak T
Clin Infect Dis; 2010 Jan; 50(2):229-38. PubMed ID: 20025527
[TBL] [Abstract][Full Text] [Related]
29. Do Polymicrobial Intra-Abdominal Infections Have Worse Outcomes than Monomicrobial Intra-Abdominal Infections?
Shah PM; Edwards BL; Dietch ZC; Guidry CA; Davies SW; Hennessy SA; Duane TM; O'Neill PJ; Coimbra R; Cook CH; Askari R; Popovsky K; Sawyer RG
Surg Infect (Larchmt); 2016 Feb; 17(1):27-31. PubMed ID: 26397376
[TBL] [Abstract][Full Text] [Related]
30. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
[TBL] [Abstract][Full Text] [Related]
32. Tigecycline: an antibiotic for the twenty-first century.
Dryden M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
[TBL] [Abstract][Full Text] [Related]
33. Tigecycline: a critical update.
Shakil S; Akram M; Khan AU
J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
Mayne D; Dowzicky MJ
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
[TBL] [Abstract][Full Text] [Related]
35. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort.
Vidal E; Torre-Cisneros J; Blanes M; Montejo M; Cervera C; Aguado JM; Len O; Carratalá J; Cordero E; Bou G; Muñoz P; Ramos A; Gurguí M; Borrell N; Fortún J;
Transpl Infect Dis; 2012 Dec; 14(6):595-603. PubMed ID: 22650416
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score-Matched Analysis.
Solomkin J; Mullins CD; Quintana A; Eckmann C; Shelbaya A; Ernst FR; Krukas MR; Reisman A
Surg Infect (Larchmt); 2016 Aug; 17(4):402-11. PubMed ID: 26981640
[TBL] [Abstract][Full Text] [Related]
37. [Epidemiology and risk factors of patients with intra-abdominal postsurgical infection treated with tigecycline: a cohort study].
Torres G; Paredes M; Hernández A; García C; Sánchez Bueno F; Canteras M; Parrilla P; Gómez J
Rev Esp Quimioter; 2017 Feb; 30(1):28-33. PubMed ID: 28010058
[TBL] [Abstract][Full Text] [Related]
38. Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment.
Silva-Nunes J; Cardoso T
BMC Infect Dis; 2019 Nov; 19(1):980. PubMed ID: 31752716
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial Monotherapy versus Combination Therapy for the Treatment of Complicated Intra-Abdominal Infections.
Petite SE; Bauer SR; Bollinger JE; Ahrens CL; Harinstein LM
Pharmacotherapy; 2016 Nov; 36(11):1138-1144. PubMed ID: 27726155
[TBL] [Abstract][Full Text] [Related]
40. Re-defining tigecycline therapy.
De Rosa FG; Corcione S; Di Perri G; Scaglione F
New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
